Trial assesses safety and efficacy of non-Hodgkin lymphoma t
Recent results from a clinical trial provide new data that confirm the safety and efficacy of a treatment for non-Hodgkin lymphoma.

According to the research team which conducted the trial, ibrutinib, which acts as a chemotherapy-free treatment for Waldenstrom’s macroglobulinemia, may be a viable choice for patients who do not respond to traditional treatments. Over the course of seven months, 31 patients with a median age of 67 participated in a multicenter study that aimed to test their tolerance and response to the drug.

“This study provided evidence that single-agent ibrutinib is a highly effective and well-tolerated treatment in patients with rituximab-refractory Waldenstrom’s macroglobulinemia,” said Shuo Ma, associate professor of medicine in the division of hematology/oncology, and a member of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University...